Get the Whole Story Here.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Artificial Intelligence
Social Media
Stock Markets
Natural Disasters
Donald Trump
Baseball
Senate
Cryptocurrency
Immigration
Innovation
Education
Housing
Published • loading... • Updated

Sacituzumab Govitecan Combo Shows Pathologic Responses in Early-Stage TNBC

Summary by cancernetwork.com
Data from the NeoSTAR trial showed no new safety signals with sacituzumab govitecan plus pembrolizumab for early-stage triple-negative breast cancer.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
targetedonc.comtargetedonc.com

Sacituzumab Govitecan/Pembrolizumab Show pCRs in Early TNBC

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Read Full Article
cancernetwork.comcancernetwork.com

Sacituzumab Govitecan Combo Shows Pathologic Responses in Early-Stage TNBC

Data from the NeoSTAR trial showed no new safety signals with sacituzumab govitecan plus pembrolizumab for early-stage triple-negative breast cancer.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

cancernetwork.com broke the news in on Sunday, June 1, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Breast Cancer

Breast Cancer

News
For You
SearchBlindspotLocal